Scotland boosts bio-based manufacturing wi...Biotech companies in Scotlands thriving bio-based manufacturing have been invited to apply for up to £1m funding within the Launchpad programme. more ➔
Memo Therapeutics AG raises CHF25mSwiss Memo Therapeutics AG will use CHF25m raised in a new Series C financing to complete a Phase II study with Anti-BKV for prevention of virus-induced graft damage. more ➔
microRNA could offer a safe target in athe...Researchers led by Wolfgang Enard from LMU Munich have identified a microRNA-based mechanism that drives atherosclerosis by weakening the integrity of blood vessel walls. more ➔
Cellectis and AstraZeneca in US$2.2bn dealAstraZeneca plc has paid French cancer cell therapy developer Cellectis SA US$25m upfront and US$220m in equity in an US$2.2bn R&D deal for up to ten cell and gene therapies. more ➔
Alfasigma SpA set to take over Galapagos p...Italian pharma company Alfasigma SpA has signed a letter of intent to acquire the filgotinib business from Galapagos. more ➔
Abingworth raises $356m for new CCD fundRaising $356m through a new Clinical Co-Development Co-Investment Fund (CCD-CIF), Carlyle-subsidiary Abingworth has extended its capital base for late-stage clinical bio-pharma programmes. more ➔
TCMStudy links TCM with effects on protein ne...By mapping out associations between human protein networks and herbs used in traditional Chinese medicine (TCM), a Chinese-Bulgarian team can predict relief on various disease symptoms. more ➔
Cancer vaccinesBioNtech reports Car-T/mRNA booster study...BioNtech SE has reported preliminary Phase I/II results with BNT211-01 (NEO-PTC-01) and CarVAC at ESMO conference in Madrid more ➔
M&ARoche acquires Telavant Holdings to win TL...Analysts describe as sporting the €7.1bn for Roche AG’s acquisition of Roivant subsidiary Telavant Holdings. more ➔
AMRUK boosts AMR defenses with £30m PACE ini...In an effort to address the global health threat of antimicrobial resistance (AMR), Innovate UK, LifeArc, and Medicines Discovery Catapult have jointly launched the PACE (Pathways to Antimicrobial Clinical … more ➔
